Contact: Yaa Acheampong, Research Manager: y.acheampong@nhs.net

Current research studies

Aim:

To compare using MTX and gefitinib together with using MTX and placebo (dummy drug), to study how gefitinib works in the body.
To assess whether the two drugs together are better than MTX with placebo at treating the EP without the need for surgery. We will also compare how long the hCG level takes to decrease, number of hospital visits and need for further MTX.

Recruitment:

  • Clinical decision made for treatment of tubal EP with MTX
  • 18-50 years at time of randomisation
  • Diagnosis of either;
    • 1. definite tubal EP (extrauterine gestational sac with yolk sac and/or embryo, without cardiac activity on USS) or
    • 2. clinical decision of probable tubal EP (extrauterine sac-like structure or inhomogeneous adnexal mass on USS with a background of sub optimal serum hCG concentrations (on at least 2 different days))
  • ​​​​​​​​​​​​​​Pre-treatment serum hCG level of 1000–5000 IU/L (within 1 calendar day of treatment)
  • Clinically stable
  • Haemoglobin between 100 and 165 g/L within 3 calendar days of treatment

Aim:

To try and find out if anticoagulant (“blood thinning”) treatment reduces the risk of miscarriage in pregnant women who have inherited thrombophilia and who have had at least two consecutive or non-consecutive miscarriages.

Recruitment:

  • Female patients aged between 18-42
  • ≥2 miscarriages and/or IUFDs
  • Inherited thrombophilia

Aim:

To evaluate the impact on sexual function with ‘Early-Salpingectomy’ and ‘Delayed-Oophorectomy’, as a two-step ovarian cancer prevention strategy in premenopausal women at high-risk of ovarian cancer.

Recruitment:

  • Women at increased risk of OC: BRCA1/BRCA2 mutation carriers; RAD51C/RAD51D/BRIP1 mutation carriers; strong family history* of breast and OC or OC alone.
  • Premenopausal ≥30years.
  • Completed family (for surgical arms).

Aim:

To compare the effectiveness of letrozole versus clomifene, metformin versus placebo and letrozole plus metformin versus clomifene plus metformin, in woman with anovulatory PCOS and infertility on live birth rate (≥ 34 weeks of gestation).

Recruitment:

  • Women diagnosed with PCOS (according to Rotterdam criteria) and evidence of anovulation (anovulation is defined as irregular cycles lasting <21 or more than 35 days or less than 8 periods per year OR absence of raised serum progesterone greater than 20nmol/l 7 days prior to a period)
  • Presentation with infertility or wishing to conceive
  • Male partner with normal sperm count (≥ 15 million) and progressive motility (≥ 32%) in the last 3 years

Aim

To determine if doxycycline administered prior to conception improves pregnancy outcome in women with recurrent miscarriage associated with chronic endometritis and explore the mechanisms by which it could prevent miscarriage.

Recruitment

  • Age (≥18 to <42)
  • 2 or more (consecutive first trimester) miscarriages
  • Not currently pregnancy
  • No known treatable cause of miscarriage 
  • No uncontrolled disease
  • Happy to use barrier contraception for 3 months
  • Not taking antibiotics
  • No known allergy or contraindication to doxycycline
  • Menstrual cycle between 21-42 days

Aim

To assess whether hydroxychloroquine may help improve pregnancies in women with antiphospholipid antibodies (aPL).

Recruitment

  • Women with known aPL who are planning pregnancy.